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Abstract 
 We examined the role of MALAT1, a highly conserved nuclear lncRNA, in chronic diabetic 
complications affecting the heart and kidneys, specifically with respect to inflammatory 
cytokine production. Endothelial cells, exposed to various glucose levels, and MALAT1 
knockout mice and controls, with or without streptozotocin-induced diabetes were examined. 
Endothelial cells cultured with high glucose, and renal and cardiac tissue from diabetic mice 
showed increased inflammatory cytokine (eg. IL-6, IL-1β, TNFα) production along with 
transient MALAT1 upregulation. This was confirmed by both transcript and protein analyses, 
and such changes were prevented in the MALAT1 knockout diabetic animals. In the 
MALAT1 knockout animals, diabetes-induced cardiac dysfunction was also prevented. We 
further identified that such actions of MALAT1 are mediated by specific downstream 
molecules including SAA3 and p53. The data from this study provided direct evidence to the 
importance of MALAT1 in the pathogenesis of chronic diabetic complications involving the 
heart and kidneys. 
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Chapter 1  
1 Introduction 
 
1.1 Diabetes Mellitus 
Diabetes mellitus is a chronic metabolic disease characterized by insulin deficiency. The 
disease is divided into one of two broader subcategories, type 1 diabetes and type 2 
diabetes. Type 1 diabetes results from absolute insulin deficiency due to specific auto-
immune destruction of the pancreatic β-cells; therefore, the body loses the ability to 
create and secrete insulin [1]. This is also classified as a type IV hypersensitivity reaction 
as the autoimmune destruction is T-cell mediated [2]. In type 2 diabetes, there is no loss 
of β -cells, but rather through poorly characterized mechanisms, patients develop a 
resistance to their body’s insulin in important glucose-uptake organs such as the liver, 
adipose, and skeletal muscle. Whether through destruction of islets in type 1, or 
resistance to insulin in type 2, hyperglycemia results in diabetes through inadequate 
glucose uptake into the tissues leading to excessive glucose in the circulation, which 
leads to cellular damage. This chronic disease is both initiated and propagated by 
inflammatory cells and cytokines which are elevated and sustained at a low-grade 
throughout the disease [3]. Endothelial cells (ECs) are the principal cell type affected by 
hyperglycemia due to their protective barrier function [4].  
 
1.1.1 Epidemiology 
Diabetes mellitus is one of the fastest-growing health issues in the world, affecting 
around 400 million people worldwide, and is the seventh leading cause of death in the 
USA [5].The incidence of diabetes increases with the obesity epidemic and is very 
serious due to the increased risk for cardiovascular events, and the poor response to 
interventions. It is also a tremendous burden on the healthcare system where it consumes 
1of every 12 global health care dollars spent [6]. As a result of hyperglycemia in both 
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type 1 and in type 2 diabetes, end-organ damage leads to significant mortality and 
morbidity in the diabetic populations. Such end organ damage leads to afflictions of the 
retina, kidneys, heart, and large blood vessels [7,8]. 
 
1.2 Diabetic Complications 
Diabetic complications lead to functional and structural alterations through defects that 
arise due to chronic hyperglycemia. Diabetic complications arise in most individuals with 
diabetes, the complications themselves varying in degrees of severity [9,10]. 
Complications tend to occur later in the patient’s life due to the slow progression of 
diabetes; however, complications can cause significant morbidity as well as mortality. 
This thesis focuses on the major complications affecting the eye, kidney and heart.  
 
1.2.1 Pathogenetic Mechanism 
Despite the great differences and various tissues these complications affect, diabetic 
complications stem from the same pathways, beginning with hyperglycemia and 
oxidative stress. The four well studied pathways are the Hexosamine, Protein Kinase C, 
AGE (Advanced Glycation End Products), and Polyol pathways [11,12]. Each of these 
pathways culminates in an increase in oxygen radicals, which lead to oxidative stress. 
These pathways lead to an increase in pro-inflammatory molecules such as tumor 
necrosis factor alpha (TNFα), interleukin-six (IL-6), and interleukin eighteen (IL-18) 
[13,14]. While each of these pathways and the inflammatory molecules have all been 
studied in great detail in the context of diabetes, there is a knowledge gap in their 
respective regulatory roles in the nucleus; therefore, understanding such processes could 
provide novel insight into the progression of low grade chronic inflammation in diabetes. 
 
The four pathways mentioned above are responsible for a dysregulation of the 
mitochondrial electron transport chain and a subsequent overproduction of superoxide 
and reactive oxygen species (ROS) [15]. Oxidative stress leads to endothelial dysfunction 
that is a key development in diabetic microvascular disease [16]. This oxidative stress is 
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the direct result of hyperglycemia, which greatly influences normal transfer of protons in 
the mitochondria. Due to excess glucose going through glycolysis, and the formation of 
pyruvate NADH and FADH2, the voltage across the inner mitochondrial membrane 
increases which blocks electron transfer from complex III [17]. The overcharged 
membrane stops pumping creating a halt in normal electron transport chain that leads to 
molecular oxygen only accepting one electron from Coenzyme Q and the formation of an 
O- anion [17.18]. This generates ROS at elevated levels and can lead to cell toxicity or 
destruction of macromolecules. Very high levels of radical species can lead to DNA 
damage and an increase in cell death in susceptible cells and tissues [19].  
 
The presence of oxygen radicals also acts as a danger associated molecule pattern 
(DAMP) which can be detected by innate immune receptors such as Toll-like receptors 
(TLRs), and Nod-like receptors (NLRs) [20]. When activated, these receptors signal to 
downstream transcription factors that increase production of inflammatory cytokines and 
related proteins. The production of ROS in a single cell triggers the activation of internal 
TLRs and NLRs. The activation of these receptors signals to downstream pathways 
including interferon regulatory factor 3 (IRF3) and nuclear factor kappa B (NFκB) which 
both translocate in to the nucleus and act as transcription factors for inflammatory genes. 
This transcription leads to increased production and excretion of molecules like TNFα, 
IL-6, and IL-1β, which influence development of inflammatory cells and promote a pro-
inflammatory environment. 
 
1.2.2 Diabetic Nephropathy 
Diabetic nephropathy leads to functional and structural alterations of the kidney through a 
variety of metabolic defects. At the transcriptional level damaged cells produce 
vasoactive and fibrogenic factors changing renal structure and function and ultimately to 
renal failure [21]. Diabetic nephropathy is the leading cause of renal failure in the 
western world [22]. Microalbuminuria is an early manifestation in diabetic nephropathy 
and leads to damage to glomeruli as well as hyperfiltration [23,24]. Later, patients 
develop increasing proteinuria, reduced glomerular filtration rate and renal failure. As in 
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all diabetic complications, hyperglycemia is the most important factor leading to diabetic 
nephropathy [21,24].  Hyperglycemia causes multiple metabolic defects which are 
exacerbated by oxidative stress [21,24]. Glucose-induced EC dysfunctions result in 
increased production of vasoactive factors, inflammatory mediators and extracellular 
matrix (ECM) proteins [21,23,24].   
 
1.2.3 Diabetic Retinopathy 
Diabetic retinopathy is the leading cause of blindness in individuals under age 65 [9]. 
Likely as a result of the microvasculature of the eye, diabetic retinopathy is the most 
commonly seen manifestation of diabetic microvasculature disease. Because of this, more 
than 60 percent of diabetic individuals manifest some complication of damage of the 
retina as a result of hyperglycemia. Diabetic retinopathy manifests in progressive stages: 
Preclinical, non-proliferative, and proliferative retinopathy, each stage ranging from mild 
to severe. Preclinical retinopathy is characterized by basement membrane thickening, 
pericyte and EC loss [9,11,12,25]. Non-proliferative retinopathy is characterized by 
venous dilatation, beading, hemorrhages and exudates, capillary non-perfusion, and intra-
retinal microvascular abnormalities [26]. Proliferative retinopathy is characterized by 
neovascularization leading to retinal hemorrhages and retinal detachment [9,25,27]. 
Current therapies for retinopathy include anti-vascular endothelial growth factor (VEGF) 
drugs as well as laser photocoagulation and burning of the blood vessels [28].  
 
1.2.4 Diabetic Heart Disease 
Cardiac complications account for the majority of diabetes related deaths [29]. 
Consequences related to cardiac affliction in diabetes include coronary atherosclerosis, 
diabetic cardiomyopathy and autonomic neuropathy [30]. Coronary atherosclerosis 
involves the narrowing of medium sized arteries due to the accumulation of plaque in the 
intimal layer. Diabetics are more susceptible to atherosclerosis due to endothelial 
dysfunction, which decreases nitric oxide production, as well as low-grade inflammation 
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in the tissues that leads to increased levels of inflammatory cytokines like TNF-α and IL-
6 [31]. This alteration of the macrovasculature leads to ischemia and necrosis of the heart 
tissue [32].  
 
Autonomic diabetic neuropathy results from afflictions of the small vessels. Impaired 
blood flow regulation in small capillary vascular beds decreases oxygen received by 
tissues such as the heart and integumentary system. These individuals are more 
susceptible for sudden cardiac death due to poor tissue perfusion [29,30]. 
Cardiomyopathy is a disease of the myocardium in patients with diabetes which is not 
explained by coronary atherosclerosis. Rather, the complication is hallmarked by 
impairment of the myocardial contractile properties, cardiomyocyte hypertrophy, 
interstitial and perivascular fibrosis, myocyte necrosis and microangiopathic lesions such 
as capillary basement membrane thickening [33]. 
 
1.2.5 Regulation of Gene Expression in Diabetes 
Endothelial cells undergo a great number of transcriptional alterations in gene expression 
to compensate for changes that arise due to diabetes and hyperglycemia [11,25]. Many of 
these changes are attributed to oxidative stress, which is known to cause changes in cell 
cycle regulation and survival. Due to an increase in DNA damage from ROS, checkpoint 
regulator proteins are elevated to prevent mutations. P53 is such an enzyme that is 
elevated in diabetes and leads to an increase in apoptotic cell death should DNA repair 
pathways not resolve the problem. As such, proteins involved in break repair and 
mismatch repair are also elevated including Artemis, DNA ligase IV, and replication 
protein A [34,35].  
 
Changes in gene expression are understandably accompanied by changes in chromatin 
organization. DNA and histones are both modified through epigenetic changes to allow 
for alterations in chromatin packing and accessibility to different genes [36,37]. One 
example of this is the loss of heterochromatin following DNA damage by oxidative 
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stress. Trimethylation at histone 3 lysine residue 9 (H3K9me3) is associated with 
decreased gene expression at that locus although the same epigenetic modification at 
other loci may have the opposite effect [38]. In diabetes, the loss of methylation at H3K9 
leads to increased gene expression due to the loss of heterochromatin. Mice that were 
diabetic on a db/db background (Mice with homozygous point mutations in the leptin 
receptor) were found to have significantly decreased levels of H3K9me3 at inflammatory 
gene promoters including IL-6 and monocyte chemoattractant protein-1 (MCP1). 
However, the transcript and protein expression of these inflammatory cytokines were 
significantly increased [39]. 
 
Another common epigenetic modification is the acetylation of histones. Acetylation of 
lysines on histone 3 is more commonly associated with gene activation. However, to 
some degree this is still regulated by the specific histone acetylases and histone 
deacetylases, which are recruited to the site [37]. P300, a protein with a histone 
acetyltransferase domain was found to be expressed at significantly higher levels in cells 
treated with high glucose. This increase was accompanied by an elevated expression in a 
number of potential downstream targets including ECM proteins and angiogenic factors 
[40]. A separate study has also provided evidence suggesting that p300 may be involved 
in increased NF-κB promoter activity [41].    
 
In addition to histones, DNA can be directly modified in diabetes either through 
epigenetics or through oxidative stress, leading to the formation of Hoogsteen or non-
conventional base pair arrangements [42]. One common example are guanine-
quadruplexes, which occur in G-rich sequences. While certain transcription factors bind 
with higher affinity to these structures, they also prevent proper chromatin arrangement 
and inhibit heterochromatin formation. This leads to changes in gene expression 
[42].ROS can also modify DNA through alterations in DNA methylation. DNA is 
primarily methylated at target cytosines in CpG dinucleotide rich regions (CpG islands) 
[43]. In healthy cells these CpG islands are frequently hypomethylated and lead to gene 
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expression; however, many of these sites are hypermethylated in diabetes leading to 
decreased expression of specific genes such as Sirtuin 1 (SIRT1), forkhead box P3 
(FOXP3), and peroxisome proliferator-activator receptor gamma coactivator 1-alpha 
(PPARGC1A) [44-46]. This is likely due to their G rich regions that are conducive to 
forming guanine-quadruplexes as described above which greatly impair the activity of 
demethylases [47]. DNA methyl transferases (DNMTs) and demethylases are the enzyme 
classes responsible for the addition and removal of these methyl groups. Upon exposure 
to ROS agents such as peroxide, DMNT1 binds with stronger affinity to chromatin, 
specifically at CpG rich regions [48]. Furthermore, H2O2 treatment and damage triggers 
the formation of a complex including DNMT1, SIRT1, and Enhancer of zeste 2 (EZH2), 
which removes these proteins from their normal locations in the nucleus and further 
repress gene expression [49].  
 
Micro RNAs are also frequently altered in diabetic complications and have been shown 
to play important roles. MiRNAs have been implicated in many relevant pathways in 
diabetes from fat metabolism and cholesterol synthesis to insulin secretion and immune 
cell recruitment [50, 51]. MiRNAs play important roles in proliferation, differentiation 
and cell signaling, all of which are vital processes in diseases including diabetes [52, 53]. 
MiR-133 has been implicated in cardiomyopathy and diabetic nephropathy after it was 
found to be aberrantly expressed in diabetic heart and kidney tissues [54]. MiR-200b 
isoform has also been implicated in both diabetic retinopathy and cardiomyopathy where 
it regulates VEGF [55.56]. The importance of miRNAs in diabetes is further supported 
by studies using Dicer, an enzyme that is required in the biogenesis of miRNAs. Mice 
deficient in Dicer have significant proteinuria, hyperfiltration, and damage to their 
glomeruli, all of which are seen in diabetic kidney disease [57,58]. Our lab has previously 
shown roles for multiple miRNAs in chronic diabetic complications. In this research, we 
focus on long non-coding RNA.  
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1.3 Non-Coding RNA 
Most of the eukaryotic genome is transcribed yielding thousands of transcripts of varying 
sizes; however, the vast majority of these transcripts have no protein-coding capacity 
[59]. Non-coding RNAs (ncRNAs) were considered to be 'junk DNA' or ‘noise’ until 
recently when it was discovered that they not only make up the majority of the human 
genome, but many of them are highly conserved and functional [59-61]. NcRNAs are 
RNA molecules of any size that are transcribed from DNA, but do not undergo 
translation in to a stable product. In addition, many ncRNAs show cell type specific 
expression, complex organizational patterns, and association with human diseases [59-
61].  General classes of ncRNAs include microRNA (miRNA), short interfering RNA 
(siRNA), piwi-interacting RNA (piRNA), and long non-coding RNA (lncRNA [62,63]. 
The principal ncRNAs involved in pre and post-transcriptional regulation are further sub 
categorized based on size. NcRNAs less than 30 nucleotides in length are termed short, 
those ranging from 31 to 200 nucleotides are called medium, and those of length greater 
than 200 nucleotides are classified as long ncRNAs [64]. All groups of ncRNAs have 
been shown to serve a wide variety of functions in all tissues. Such functions include 
heterochromatin condensing, histone modification, DNA methylation, gene silencing, and 
protein organization [61,65,66]. 
 
1.4 Long non-coding RNA 
LnRNAs are loosely defined as any RNA molecule which is greater than 200 nucleotides 
and does not code for a functional protein product [67]. As such, the group is very diverse 
containing molecules continuing 200 nucleotides to well over 10 thousand nucleotides. 
Occasionally molecules once considered to be non-coding are found to code for a protein 
which also changes which molecules are in this group. As such, there are still well over 
4000 characterized unique lncRNAs in humans that make up both the majority of the 
genome in percent composition of known transcripts, and total unique members 
compared to any other group [64]. As with most genes, lncRNAs are frequently regulated 
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both spatially and temporally by both the specific tissue or cell type, and the stage of 
development. 
 
1.4.1 Long non-coding RNA location in genome 
LncRNAs are also found all across the genome on all chromosomes and can be 
categorized based on their location. The five principal locational types of lncRNAs are 
intronic, intergenic, antisense, bidirectional, and senses lncRNAs [68]. As the name 
suggests, intronic lncRNAs are found in intronic regions of protein-coding genes and are 
produced through alternative splicing of pre-mRNA. The can be on either the sense or 
anti-sense strand or in the opposite direction as the protein-coding gene, but they do not 
overlap with the protein coding gene [69]. Intergenic lncRNAs are located in distinct 
transcriptional segments from coding genes. They have their own unique gene sites and 
are at least 10kb removed from the nearest protein coding gene [65,69]. Antisense 
lncRNAs are on the complementary sequence to the coding sense stand. They may 
overlap with coding exons but their segments are spliced together to form a non-coding 
product [70,71]. Bidirectional lncRNAs originate from divergent transcription from the 
promoter of a protein-coding gene. As a result of this, they are usually very close in 
proximity to, and on the opposite strand as the coding gene [69,72]. Sense lncRNAs 
overlap the sense strand sequence of a protein-coding gene. The lncRNA can overlap a 
portion of, or be entirely bound by the protein coding gene [72].       
 
1.4.2 Long non-coding RNA Functions 
In spite of their overwhelming prevalence, the functions of lncRNAs remain relatively 
unclear. Even in cases where functionality is known, it is highly probable that due to their 
sheer size they are capable of multiple diverse functions [73]. While they do not code for 
proteins themselves, they are able to regulate protein and non-protein coding genes 
through both -cis and -trans effects [74]. LncRNAs influence gene expression by 
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signalling and regulating gene expression, act as decoys to inhibit specific interactions, 
guiding proteins to specific chromatin sites, and scaffolding to organize and complex 
molecules in specific cellular compartments [62,64,66]. Through these mechanisms and 
potentially others, lncRNAs are able to influence a variety of cellular functions. 
However, their role in diabetic complications remains under investigated. In the 
following paragraphs I will discuss specific lncRNA relevant to this thesis. 
 
1.5 MALAT1 
1.5.1 Malat1 structure and conservation 
MALAT1 (Metastasis associated lung adenocarcinoma transcript 1, NEAT2) was first 
identified in 2003 in early-stage non-small cell lung cancer cells [75]. MALAT1 is found 
on chromosome 11q13.1 where it encodes an 8.7 kb transcript. In mouse, it is found on 
chromosome 19 and is slightly smaller at 6.98 kb though nearly 5kb are identical between 
mouse and man and this high level of conservation is found in mammals. Regions of 
MALAT1 can be found as far back in evolution as frogs and fish [76,77]. In addition to 
not localizing to the cytoplasm, MALAT1 has no functional ORFs and lacks the ability to 
bind ribosomes which have added to its classification as non-coding [74,76,78]. 
 
MALAT1 is encoded on a single exon and does not undergo any significant known 
alterations, modifications, or splicing. The gene also encodes nearly no repeat elements. 
Some studies have reported that a small 61-80 nucletotide RNA molecule is cleaved and 
may enter the cytoplasm but remains untranslated [79,80]. This small RNA has been 
called MALAT1-associated small cytoplasmic RNA (mascRNA). MascRNA seems to be 
a likely candidate for a transfer RNA (tRNA) derived element [80]. This postulated 
molecule is found at 3’ end of the MALAT1 RNA, anterior to the 3’ helix motif. 
MALAT1 and its neighboring gene nuclear enriched abundant transcript 1 (NEAT1), have 
been postulated to have arisen from a duplication event in the genome due to their unique 
positions beside each other in the mammalian genome, and similar length [81]. However, 
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MALAT1 and NEAT1 share almost no sequence homology beyond a small 3’ region [77].  
(lncRNA) MALAT1 is highly stable for an RNA molecule with half-lives reported 
between 9 and 24 hours [82]. Much of this stability is likely due to both its strict presence 
in the nucleus where there is less overall degradation, as well as a stable triple helix 
secondary motif at its 3’ terminus [68,83,84]. Because of this, there is also not ability for 
this RNA to be polyadenylated [83]. In addition to its unique helix motif, MALAT1 has a 
distinct sequence or secondary structure that allows it to localize to specific foci known as 
paraspeckles [66]. At these nuclear speckles, MALAT1 complexes with other molecules 
including its neighboring gene NEAT1 [66]. This secondary structure, along with its 
tremendous length, makes MALAT1 a poor target for knockdown experiments which are 
not sufficient to uncover a function for the lncRNA [85,86]. The gene’s expression can be 
verifiably eliminated with the use of multiple zinc finger nucleases [85]. Mouse knockout 
models of MALAT1 have been generated and are not only non-lethal, but also show no 
observable phenotype, including the cells’ ability to form nuclear paraspekles [66,86]. To 
date these models have only been used to study a small number of diseases and processes.  
  
1.5.2 Malat1 function and interactions 
MALAT1 is found at high levels in nearly all tissues and cells with some of the highest 
reported in the colon, liver, immune cells, kidney, lung, brain, and heart. Because of this, 
it remains to be seen whether MALAT1 exerts a single function in all tissues, or a tissue 
specific role dependent on the tissue it is in. Several functions and interactions have been 
found for this molecule with most of them involved in cancer, where it has been primarily 
studied to date. 
 
In cancer, MALAT1 has been shown to regulate metastasis and cell motility. As such, 
MALAT1 had been reported to be elevated in many cancers including breast cancer, 
cervical cancer, colorectal cancer, liver cancer, neuroblastoma, osteosarcoma, pancreatic 
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cancer, prostate cancer, and gastric cancer [76,84,87,88]. In each of these cancers, 
MALAT1 is associated with a poor prognosis, whereby as the level of transcript increases, 
patient survival rate decreases [89]. Because of this MALAT1 has been termed an 
oncogene [88,90]. One study has also proposed that MALAT1 is involved in the 
alternative splicing and expression of other oncogenes [89,90]. MALAT1has also been 
shown to be of importance in other diseases including pre-eclampsia, ischemia, and 
sinoatrial node disease. One study also found elevated levels of MALAT1 in the 
hippocampus, cerebellum, and brainstem of human alcoholics [91].  
 
One of the most notable proteins involved in regulation of MALAT1 is p53. One study 
found that when p53 was overexpressed MALAT1 levels decreased significantly [92]. A 
considerably enriched p53 binding locus called BS-p53-1 was also shown to be enriched 
in the MALAT1 promoter [92]. A separate study found a deletion of MALAT1 lead to 
increased activation of p53 [93]. This association is further strengthened by numerous 
studies that knockout or knockdown MALAT1 and report a decrease in proliferation and 
cell survival [89]. MALAT1 knockdown cells also show higher sensitivity to apoptosis 
inducing agents [89]. Together these findings suggest MALAT1 may be both regulated, 
and a regulator of p53. This may help to explain MALAT1’s upregulation in diseases like 
cancer where cell death is suppressed, but its downregulation in ischemia and other 
disease characterized by chronic cell death.  
 
Other functional roles for MALAT1 that have been reported include its ability to regulate 
TGF-β signaling via SMAD2/3 [94]. In addition, it has been shown that MALAT1 
regulates serum amyloid A3 (SAA3) [95]. SAA3 stimulates IL-6 and TNFα production 
through NFκB. MALAT1 has also been shown to regulate its neighboring gene NEAT1 
through cis interactions [66]. 
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1.6 Rationale 
Diabetic complications involve a large number of alterations to gene expression, all of 
which are mediated through proteins and molecules resident in the nucleus. LncRNAs are 
a relatively unstudied class of molecules, many of which are highly conserved and either 
initiate or reside in the nucleus. We identified MALAT1 in a transcript array as a non-
coding RNA which is aberrantly expressed in endothelial cells under hyperglycemic 
stress [Figure 1]. MALAT1 is also one of the lncRNAs with the highest expression across 
multiple tissues in mammals and is dysregulated in multiple diseases.  
Preliminary work completed by our lab showed that MALAT1 expression is elevated at 
specific points over a time course treatment of high glucose in endothelial cells. 
Furthermore, the increase in MALAT1 transcript expression correlated with increases in 
multiple proteins including inflammatory cytokines such as IL-6 and TNFα. Using 
MALAT1 specific antisense oligonucleotides, MALAT1 levels were then reduced, and 
this reduction correlated to a similar reduction in these inflammatory cytokines [95]. 
Recently, another study has confirmed this finding as well, showing that TNFα 
expression in splenocytes was lower in mice lacking MALAT1 compared to WT mice 
[96]. Based on these rationales, we developed the following hypothesis: 
 
1.7 Hypothesis 
MALAT1 is an important regulator of inflammatory cytokines in chronic diabetic 
complications. 
 
 
 
 
14 
 
1.8 Specific Aims 
 
1. To investigate the role of MALAT1 in the production of inflammatory cytokines in 
endothelial cells exposed to high glucose. 
2. To investigate the role of MALAT1 in the production of inflammatory cytokines and 
subsequent organ damage in mice with diabetes.  
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Chapter 2  
2 Material and Methods 
 
2.1 Animal Studies 
Through collaboration with Dr. Spector (Cold Spring Harbor Laboratory, Cold Spring 
Harbor, New York, USA), mice were obtained that have a ~3 kb deletion in the 5’ end and 
promoter of the MALAT1 gene [66].This homozygous deletion is a global knockout 
eliminating MALAT1 transcript expression in all tissues. The mice were generated on a 
C57/BL6 background. Diabetes was induced in 10-week old mice using 5 injections of 
low dose streptozotocin (STZ) (Sigma, Oakville, Ontario, Canada; 50 mg/Kg IP, Na 
Citrate buffer, pH5.6) on consecutive days, controls receiving and equal volume injection 
of buffer only [97]. Diabetes was evaluated based on a 4 hour fasting blood glucose level 
greater than 20mmol/L. Control mice had glucose levels less than 10mmol/L. Mice were 
all age matched and only male mice were used.  The following groups of animals were 
used: a) Non-diabetic control animals, b) STZ induced diabetic control animals c) 
MALAT1 knockout mice, d) MALAT1 knockout mice with STZ- diabetes. All animals 
were housed with access to standard diet (Harlan 2018 rodent diet) and water ad. Libitum. 
Animals were monitored up until the time of sacrifice at either 1 week, 2 weeks, 4 weeks, 
or 8 weeks post diabetes. Blood glucose levels, urine ketones, and body weight were 
frequently recorded and monitored. Mice were euthanized by Forane™ (Baxter, Toronto, 
Ontario, Canada) overdose and asphyxiation. Following sacrifice, blood, kidney, heart, 
retina and other major organs were collected. Small portions of the tissues were snap 
frozen for RNA and protein analyses and the remaining tissue fixed in 10% formalin to be 
used for other experiments. All procedures were approved by the University’s Animal 
Care Committee [97].  
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2.2 Cell Culture 
Human umbilical vein endothelial cells (HUVEC) and human retinal endothelial cells 
(HREC) were purchased frozen from Lonza (Jackson, Wisconsin, USA), and Olaf 
Pharmaceuticals (Worcester, Massachusetts, USA) respectively. Cells were grown at 37C, 
5% CO2, in EBM-2 (Lonza) supplemented with 10% fetal bovine serum (FBS). Cells at 
passages 4, 5, and 6 were used for experiments and were plated at a density of 2,500 
cells/cm2. Once the cells had reached a confluency of 75%, they were serum starved for a 
24-hour period. Following this, D-Glucose was used to stimulate cells at concentrations of 
5ug/ml (Normal Glucose) or 25ug/ml (High Glucose). Cells were cultured for 6 hr, 12 hr, 
24 hr, or 48 hr in the treated media before harvest for experiments [98].   
 
2.3 RNA Isolation 
Mouse tissue RNA extraction was carried out using the PureLink™ RNA Mini Kit 
(Ambion Life technologies, Carlsbad, California, USA) and following the manufacturer’s 
protocol. The tissues were homogenized in Lysis buffer using either a mechanical 
homogenizer or a mortar and passage through a 20-gauge needle 4 times. An equal 
volume of 70% (v/v) ethanol was added to the homogenized tissue and then the 
homogenate was transferred to a spin cartridge to elute the liquid. RNA bound to the 
membrane of the column was washed with included buffers before eluting with molecular 
grade water. RNA purity and concentration were assessed with either a spectrophotometer 
or a nanodrop measuring at 260 and 280 nm. RNA was then immediately reverse 
transcribed to cDNA or kept at -70C.RNA extractions of HUVEC and HREC were carried 
out with TRIzol™ Reagent (Invitrogen INC, Burlington, Ontario, Canada) following the 
manufacturer’s instructions and as previously described [98].  
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2.4 DNA Isolation and Gel Electrophoresis 
DNA was extracted from mouse tail by a phenol-choloformextraction.A 1 cm piece of 
tail was digested overnight in tail buffer using protinase K heated to 45 °C. DNA was 
then extracted using phenol:choloform using a mixture of 25:24 (v/v). After vortexing 
and centrifugation at 13,000 rpm, the supernatant was collected and DNA was then 
precipitated via isopropanol and centrifuged again at 13,000 rpm for 10 minutes. The 
supernatant was removed again and the DNA pellet was then washed with 70% ethanol 
and spun down a final time. The ethanol was removed and any residual alcohol was left 
to evaporate at room temperature. DNA was then reconstituted in deionized water and 
stored at -20 °C to be used for genotyping. The sample purity was measured using the 
ratio of ultraviolet absorbance at 260 and 280 nm. The DNA concentration was 
determined measuring the absorbance at 260 nm. 
DNA gel electrophoresis was used to validate the genetic knockout of MALAT1 in mice. 
Two regions of MALAT1 were first amplified by PCR using primers specific to the 
MALAT1 DNA sequence and flanked the cut site. DNA was amplified using TaqDNA 
polymerase and PCR buffer (FroggaBio; North York, Ontario, Canada). Agarose gels 
were prepared using 1.5% agarose in TAE buffer (10 nM Tris base, 0.5 mM EDTA, 4.4 
mM acetic acid, pH 8.0). 3ul of Ethidium Bromide was added to create the gel. The wells 
were loaded with 10ul of sample (8 ul DNA, 2 ul Loading buffer), a 1 kb DNA ladder, or 
a negative control (no template). The electrophoresis was done in TAE buffer and run at 
100 volts for 1.5 hours. Gels were visualized under ultraviolet light and photos were 
taken.  
 
2.5 LncRNA Array 
RNAs were extracted using the RNAeasy miRNA isolation kit (Qiagen, Austin, TX) 
according to the manufacturer’s instruction. Custom analysis of lncRNA expression 
profiling from human retinal cells treated with high or normal glucose for 24 hours (n = 
3/group) were performed by Asuragen Inc. (Austin, TX). 
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2.5.1 LncRNA Array Protocol 
Sample labeling and array hybridization were performed according to the Agilent One-
Color Microarray-Based Gene Expression Analysis protocol (Agilent Technology) with 
minor modifications. Briefly, mRNA was purified from total RNA after removal of rRNA 
(mRNA-ONLY™ Eukaryotic mRNA Isolation Kit, Epicentre). Then, each sample was 
amplified and transcribed into fluorescent cRNA along the entire length of the transcripts 
without 3’ bias utilizing a mixture of oligo(dT) and random priming method (Arraystar 
Flash RNA Labeling Kit, Arraystar). The labeled cRNAs were purified by RNeasy Mini 
Kit (Qiagen). The concentration and specific activity of the labeled cRNAs (pmol Cy3/μg 
cRNA) were measured by NanoDrop ND-1000. 1 μg of each labeled cRNA was 
fragmented by adding 5 μl of 10 × Blocking Agent and 1 μl of 25 × Fragmentation Buffer, 
then the mixture was heated at 60 °C for 30 min, and finally 25 μl 2 × GE Hybridization 
buffer was added to dilute the labeled cRNA. 50μl of hybridization solution was dispensed 
into the gasket slide and assembled to the LncRNA expression microarray slide. The 
slides were incubated for 17 hours at 65 °C in an Agilent Hybridization Oven. The 
hybridized arrays were washed, fixed and scanned with using the Agilent DNA 
Microarray Scanner (part number G2505C). 
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2.5.2 Array Data Analysis 
 
Agilent Feature Extraction software (version 11.0.1.1) was used to analyze acquired array 
images. Quantile normalization and subsequent data processing were performed using the 
GeneSpring GX v12.0 software package (Agilent Technologies). After quantile 
normalization of the raw data P/M filtration, lncRNAswere chosen for further data 
analysis. Hierarchical Clustering was performed using the R software (version 2.15).  
 
2.6 RNA in Situ Hybridization 
RNA Fluorescent in situ Hybridization (FISH) was carried out using specific probes and 
reagents designed by Stellaris™ RNA FISH (Biosearch Technologies, Petalume, 
California, USA).To detect MALAT1 RNA, cells which were grown on coverslips were 
rinsed briefly in PBS and then fixed in 2% formaldehyde in PBS for 10 mins at room 
temperature (RT). Cells were made permeable in 70% (vol./vol.) Ethanol diluted in DEPC 
treated water overnight at 4°C. Cells were washed in Wash Buffer A for 5 minutes prior to 
hybridization. Hybridization was carried out using Stellaris™ RNA FISH probes 
dissolved in TE buffer to a concentration of 12.5 uM. Hybridization buffer was then used 
to dilute the probe to a working concentration of 125 nM and incubated with the cells in a 
moist chamber at RT for 4-6 hr. For nuclear visualization, cells were rinsed with Wash 
Buffer A and Wash Buffer B, and nuclei were then counterstained with Hoechst Stain 
(5ng/mL) for 30 minutes in the dark at RT. Coverslips were then mounted on slides to be 
visualized by immunofluorescence [99].  
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2.7 cDNA synthesis and Quantitative RT-PCR 
For real-time quantitative PCR (Q-PCR), first 1ug of total RNA was reverse transcribed to 
cDNA using High Capacity CDNA Reverse transcription Kit (Applied Biosystems Inc., 
Foster City, California, USA). The kit used a MultiScribe™ reverse transcriptase enzyme, 
as well as random oligo hexamers to amplify all RNA. Gene-specific primers sets were 
designed using NCBI basic local alignment program (BLAST) or ordered pre-designed 
from Qiagen (Toronto, Ontario, Canada), Q-PCR was carried out in duplicate using SYBR 
Green Master Mix (Clontech, Mountain View, California, USA) and run using a 
LightCycler™ 96 (RocheDiagnotstics Canada, Laval, Quebec, Canada)5. SYBR Green is a 
dye that binds to double stranded DNA and fluoresces, allowing for detection of all double 
stranded products in each cycle. Target genes were analyzed using standard curves to 
determine relative levels of gene expression. Molecular grade water was used to make up 
the volume difference in both the negative control, and no RT control. The levels of 
specific RNAs were analyzed using the Roche LightCycler™ 96 System. Individual RNA 
samples were normalized according to the level of β-actin [55]. All sequences for reverse 
and forward primers used are summarized in Table 2.1.  
 
2.8 ELISA 
Proteins were isolated from mouse tissue using radioimmunoprecipitation assay buffer. 
Protein concentration was then measured using a BCA protein assay kit (Pierce, Rockford, 
Illinois, USA). Protein concentrations were kept constant across protein lysates used for 
ELISA. For detection of IL-6 and INFγ in tissue homogenate, pre-coated plates were 
obtained from R&D systems (Minneapolis, Minnesota, USA) and the protocol was 
followed to the manufacturer’s instructions. Plates were measured at 450 and 570 nm (to 
correct for plate defects) using a plate reader. For detection of albumin and creatinine in 
mouse urine, Albuwell™ and Creatinine Companion kits were ordered from Exocell 
(Philadelphia, Pennsylvania, USA) [95].  
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Table 2.1: Oligonucleotide sequences for Real-Time PCR 
Gene Primer sequences (5’ – 3’) 
Hsa/Musb ACTB F: TGTGGATCAGCAAGCAGGAG 
R: TGCGCAAGTTAGGTTTTGTC 
Hs MALAT1  F: TCTTAGAGGGTGGGCTTTTGTT 
R: CTGCATCTAGGCCATCATACTG 
Hs TNFA  F: AGGCGCTCCCCAAGAAGACAG 
R: AGCAGGCAGAAGACGTGGTG 
Hs IL6  F: GGGGCTGCTCCTGGTGTTG 
R: CTGAGATGCCGTCGAGGATGTA 
Hs IL1B  F: GCGGCATCCAGCTACGAATCT 
R: GGGCAGGGAACCAGCATCTT 
Mus MALAT1  F: TGGGGGAGTTGTAGGCTTCT 
R: GGAGTGAGGCTTGTGGTAGG 
Mus NEAT1  F: TGGCCCCTTTTGTTCATTAGC 
R: TGGAAGGCCATTGTTTCAGG 
Mus P53  F: CTCCCTTGCTGTAGGTAGCG 
R: CGTCGATGCAGTGAGGTGAT 
Mus SAA3 F: TGACAGCCAAAGATGGGTCC 
R:TCCGGGCAGCATCATAGTTC 
Mus TNFA F: AGGCACTCCCCCAAAAAGAT 
R: CACCCCGAAGTTCAGTAGACAG 
Mus IL1B F: TTCAGGCAGGCAGTATCACTC 
R: GAAGGTCCACGGGAAAGACAC 
Mus IL6 F: ACAACCACGGCCTTCCCTACTT 
R: TCATTTCCACGATTTCCCAGAG 
aHs, Human, bMus, mouse. F, forward primer; R, reverse 
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2.9 Cardiac Ultrasound Imaging 
Echocardiographic and Doppler studies were performed using the Vevo™ 2100 imaging 
system (Visualsonic, Toronto, Ontario, Canada). All data were performed 1 week prior to 
the time of sacrifice between 1 and 5 PM. Each mouse was anesthetized in a sealed 
chamber with inhalant isolfuorane at 3% in 100% oxygen. Once anesthetized, the mouse 
was transferred and secured on its dorsal side to a heated imaging platform and isofluorane 
was maintained at 1% for the duration of the experiment. The hair of the mouse chest was 
carefully removed, and an electrode gel was applied to the chest before placing the 
transducer to the left of the sternum. At this position, images were obtained of the left 
ventricle along its long axis.  The blood flow velocity was measured using Doppler 
ultrasonography to directly measure the flow motion (Pulse Wave Doppler).  M-mode 
tracings of the heart were acquired by rotating the transducer to be perpendicular to the 
left ventricle and aligned along the short axis of the heart. Measurements were averaged 
from 3 consecutive cardiac cycles [55,100].  
 
2.10 PhyloCSF 
To measure the coding potential of MALAT1 and other gene transcripts, we used the 
previously established codon substitution frequencies (CSF) method to evaluate the 
evolutionary characteristics in their alignments with orthologous regions in other 
sequenced mammalian genomes [101,102]. CSF generates a likelihood score for a given 
sequence considering all codon substitutions observed within its alignment across multiple 
species, which was based on the relative frequency of similar substitutions occurred in 
known coding and noncoding regions. CSF compares two empirical codon models; one 
generated from alignments of known coding regions and the other according to noncoding 
regions, producing a log odds likelihood ratio reflecting which model better explains the 
alignment. The source code and executables are freely available at 
http://compbio.mit.edu/PhyloCSF.  
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2.11 Statistical Analysis 
All experimental data are expressed as mean ± SEM and were analyzed by ANOVA 
followed by Student’s t-test. Differences are represented as significant as values of 
p<0.05. 
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Chapter 3  
3 Results 
 
3.1 Screening for a potential LncRNA of interest 
Initially, we performed a custom microarray analysis (Arraystar) to identify lncRNA 
changes. To this extent, we exposed human retinal endothelial cells (HRECs) to high or 
normal glucose treatment for 24 hrs. MALAT1was identified as a gene, which was 
dysregulated in high glucose compared to normal glucose treatment.  Extracted RNAs 
were sent for quantitation by array analysis, which was designed to detect a large number 
of human lncRNAs. MALAT1 was identified as one of many lncRNAs that was 
downregulated when HREC cells were cultured in high glucose compared to cells 
cultured in low glucose [Figure 3.1].        
 This finding from the array was then tested in HUVECs where we cultured the 
cells in high and low glucose. Using qRT-PCR it was found that levels of MALAT1 were 
significantly elevated at 48 hours of high glucose (25µM) treatment compared to cells in 
normal glucose (5µM) treatment [Figure 3.2]. Since MALAT1 is highly expressed in 
nearly all tissue types, it is likely to have tissue specific functions. Furthermore, the 
targets of MALAT1 included molecules of interest in the context of diabetic 
complications including SAA3, p53 and VEGF.. Hence, alterations in MALAT1 
expression in different cell types made MALAT1 a promising candidate gene for follow 
up studies.  
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Figure 3.1: LncRNA Array Analysis 
Total RNA was isolated from HRECs cultured for 24 hours in high gluose (25 mM) or 
normal glucose (5 mM) media and sent to Aiglent Technology. mRNA was purified from 
total RNA after removal of rRNA and each sample was amplified and transcribed into 
cRNA using a mix of oligo(dT) and random priming. cRNAs were further purified 
following which slides were assembled and RNA was hybridized to a lncRNA array. After 
incubation, slides were fixed and scanned with using the Agilent DNA Microarray 
Scanner. Agilent Feature Extraction software was used to analyze acquired array images. 
Subsequent data processing was performed using the GeneSpring GX v12.0 software 
package. Hierarchical Clustering was performed using the R software. Array probes were 
sequenced through BLAST and MALAT1 was identified as a lncRNA downregulated 
more than 3 fold in the HG compared to NG treated HRECs [n=3 per group, data 
displayed as means, data points in red indicate statistical significance.] 
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Figure 3.2: MALAT1 expression in HUVEC 
Real time RT-PCR analysis of MALAT1 expression in HUVECs. Cells were exposed to 
25 mM (HG) or 5 mM (NG) glucose over a time course of 48 hours. Levels of MALAT1 
transcript were significantly increased in HG treated HUVEC at the 48 hour mark 
compared to the NG HUVEC. [* p<0.05 compared to NG, experiment performed in 
triplicate from three separate experiments, data (as a ratio to β-actin) expressed as mean ± 
SEM]. 
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3.2 MALAT1 as a gene of interest 
 
3.2.1 MALAT1 is a bona fide long non-coding RNA 
Before taking our interest in MALAT1 to a higher organism, we first set out to 
investigate MALAT1 as a gene. Using bioinformatics software PhyloCSF we confirmed 
that MALAT1 is a non-coding RNA [Figure 3.3]. PhyloCSF uses amino acid 
arrangement and substitution frequencies in evolution to generate an odds likelihood 
ration upon whether the sequence is better explained as a coding sequence or a non-
coding model. This is performed without the necessity of the sequence being similar to 
known proteins in current databases [101]. We compared it to known coding genes, as 
well as other non-coding genes. MALAT1 was identified as being 1011 times more likely 
to be explained by a non-coding than a coding model. No segment of MALAT1 was 
better explained by the coding model than the non-coding, and the greatest value was 102 
for a stretch of less than 35 nucleotides. Other non-coding genes were better explained by 
the non-coding model, and known coding genes were best explained by the coding model 
as was expected. This finding strongly suggests that MALAT1 is a non-coding transcript.  
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Figure 3.3: CSF scores 
Codon Substitution Frequencies (CSF) scores of TUBB, END1, SOX2, RGNEF, RAG1, 
TGFB2, Malat1, Mir133b, and Mir34a RNA. PhyloCSF reports scores in decibans or 
log-ratio of whether a transcript is better explained by a coding or non-coding model. A 
score of 32 indicates a transcript is 1032 times more likely to be explained by the coding 
model than non-coding model, whereas a score of -11 would indicate a transcript is 1011 
times more likely to be explained by the non-coding model than the coding model. 
PhyloCSF does not rely on homology of known coding sequences but rather evolutionary 
amino acid substitution as well as missense and nonsense substitution frequencies. 
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3.2.2 MALAT1 is present in the nucleus and is upregulated by 
glucose 
Following confirmation of its lncRNA status, we looked at MALAT1 in HRECs using 
FISH to view the localization of MALAT1 in the cell. Using specific probes we located 
MALAT1 in the cells. Such analysis showed the presence and organization of MALAT1 
in the nucleus. Our findings revealed that MALAT1 is an exclusively nuclear molecule 
and localizes to specific domains in the nucleus, which are known as paraspekles [Figure 
3.4]. MALAT1’s inability to leave the nucleus provides further evidence that it is not a 
coding gene.            
 We further used RT-PCR to look for differences in MALAT1 expression in 
HRECs to compare and validate our findings in HUVECs with a different cell type. As 
most of the diabetic complications under investigation are due to microvascular damage, 
capillary endothelial cells are of great interest in determining potential alterations of 
MALAT1 expression under high glucose conditions. RT-PCR expression of MALAT1 in 
HREC cells was consistent with our HUVEC experiment and showed a significant 
increase of MALAT1 in HREC cells at the 48hr time point when cells were treated with 
high glucose compared to control cells. Compared to normal glucose-treated cells, 
MALAT1 expression after 48hrs in the high glucose treatment was doubled. To examine 
potential downstream effects of MALAT1 upregulation, we examined several 
inflammatory cytokines. Under high glucose, these inflammatory cytokines are normally 
elevated compared to normal glucose conditions, and in diabetes this elevation leads to 
chronic levels of low grade inflammation. To this extent, we examined TNFα, IL6 and 
IL-1β. These are well established molecules that are upregulated in response to glucose in 
the context of chronic diabetic complications [103-105].We used qRT-PCR to quantify 
the expression of specific pro-inflammatory genes in the HREC cells.Expression of these 
genes increased in high glucose treatment compared to normal-glucose, and like 
MALAT1, this increase was significant in all tested genes at the 48-hour mark [Figure 
4.5].  
These findings taken together with literature on MALAT1 in other diseases and tissue 
expression made MALAT1 a promising candidate gene to look at in an in vivo model.  
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MALAT1 is a completely nuclear retained lncRNA. Malat1 probes were used to detect 
presence of malat1 in HRECs using fluorescence. Cells that had been cultured in high 
glucose (25 mM) or normal glucose (5 mM) for 48 hours were hybridized with probes for 
MALAT1 RNA (red) then counterstained with Hoechst (Blue). Images were merged 
(purple) to show completely nuclear and speckled arrangement of MALAT1 lncRNA in 
the nuclei. No visual differences could be seen between HG and NG.  
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Figure 3.4: FISH visualization of MALAT1 lncRNA localization 
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Real time RT-PCR analysis of MALAT1, IL-1β, TNFα, and IL-6 expression in HRECs 
exposed to 25 mM (HG) or 5 mM (NG) glucose over a time course of 48 hours. All four 
genes are significantly upregulated in HG treated HRECs at 48 hours compared to NG. [* 
p<0.05 compared to NG, experiment performed in triplicate from three separate 
experiments, data (as a ratio to β-actin) expressed as mean ± SEM]. 
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Figure 3.5: MALAT1 and inflammatory cytokine expression in HREC 
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3.3 In Vivo Results 
 
3.3.1 Clinical monitoring of Mice 
MALAT1 knockout mice were generated by Dr. Spector using a C57/BL6 background 
[66]. Animals were obtained and the genetic background was confirmed using DNA 
genotyping [Figure 3.6]. Control mice on a C57/BL6 background were obtained from 
Charles River to be used as controls. Diabetes was confirmed in mice by measurement of 
blood glucose levels. Diabetic animals were hyperglycemic (>20.0 mmol/L glucose) and 
had reduced body weight gain compared to control animals [Figure 3.7]. Diabetic animals 
also showed polyuria, and glucosuria. None of the animals had measurable levels of 
ketones (data not shown). Loss of MALAT1 lncRNA had no effect on either the blood 
glucose level or the bodyweight gain and knockout animals showed no differences in 
urine output. 
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Analysis of MALAT1 genotype by PCR from tail DNA. Results indicate MALAT1 wild-
type (+/+) and homozygous null (-/-) mice. DNA was resolved on a 1.5% agarose gel and 
imaged using UV light. A DNA ladder ranging from 100 to 1000 bp is shown in lane 1. 
Included base pair sizes denote predicted sizes for the KO and WT bands. 
 
bp 
501 
241 
_______+/+_______ _______-/-_______ 
________________MALAT1 Genotype________________ 
Figure 3.6: Genotype confirmation of MALAT1-/- mice 
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Figure 1.7: Clinical monitoring 
Blood glucose values and body weights of mice during the follow up period. Mice were 
injected with STZ for five days following which they were checked for hyperglycemia 
(Time 0). Mice were examined regularly for 8 weeks. Both wild-type (WT) diabetic (Dia) 
animals, and MALAT1-/- (MALAT1 KO) animals were hyperglycemic compared to 
control animals at all time points and had reduced body weight gain. Loss of MALAT1 
lncRNA had no significant effect on hyperglycemia or body weight gain in diabetes. 
[n=8-13; data expressed as mean ± SEM]. 
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3.3.2 Diabetes alters MALAT1 expression in tissues 
Using Real time PCR, MALAT1 transcript levels were measured in the heart, kidney and 
retina of WT control, WT diabetic, MALAT1 KO control, and MALAT1 KO diabetic 
animals. MALAT1 expression showed initial elevation in the kidneys from WT diabetic 
animals, followed by a decrease at 2, 4, and 8 weeks compared to the WT control tissue 
[Figure 3.8]. Both the kidney and heart tissue had significantly decreased levels of 
MALAT1 RNA in the WT diabetic animals compared to the WT control animals after 
two months of follow-up. [Figure 3.9]. There was no significant alteration in MALAT1 
expression in B6 mouse retinal tissue at 2 months. MALAT1 KO animals were devoid of 
MALAT1 expression at all time-points in all tissues.  
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Figure 3.8: MALAT1 expression in diabetes over two months 
 
Real time RT-PCR analysis of malat1in wild type (WT) control, WT diabetic (Dia), 
MALAT1-/- (MALAT1 KO) control, and MALAT1-/- diabetic mouse tissues. Transcript 
levels of MALAT1 RNA were significantly elevated in diabetic mouse kidney tissue at 1 
week, following which it was reduced compared to the WT control mouse kidney tissue. 
[*p<0.05 compared to WT control; n=3-13; data (as a ratio to β-actin) expressed as mean 
± SEM, normalized to controls]. 
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Real time RT-PCR analysis of malat1 in wild type (WT) control, WT diabetic (Dia), 
MALAT1-/- (MALAT1 KO) control, and MALAT1-/- 2-month diabetic mouse kidney, 
heart and retinal tissue. Transcript levels of MALAT1 were significantly decreased in 
diabetic mouse heart and kidney tissue compared to the WT controls. MALAT1 RNA 
was not present in any of the knockout tissues. MALAT1 expression was not 
significantly altered in the retinal tissue. [*p<0.05 compared to WT control; n=6-13; data 
(as a ratio to β-actin) expressed as mean ± SEM]. 
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Figure 3.9: MALAT1 expression in heart, kidney, and retina at 2-months 
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3.3.3 MALAT1 regulates inflammatory cytokine expression the 
tissues of chronically diabetic animals. 
Having both confirmed that MALAT1 lncRNA levels are altered in diabetes in our in 
vivo model, as well as having confirmed our MALAT1 KO model, we tested for 
transcripts with changes in expression that might be attributed to the loss of MALAT1 
RNA in diabetes. We focused on kidney and heart tissues first due to the availability of 
tissue.    
 Using RT-PCR, we measured the inflammatory cytokine transcript levels of IL-
1β, IL-6 and TNFα in both 1 and 2-month heart and kidney tissue. IL-1β and TNFα 
transcript abundances were upregulated in the WT diabetic animals compared to WT 
controls in both heart and kidney at both time points [Figures 3.10, 3.11, 3.12, and 3.13]. 
IL-6 was upregulated in both heart and kidney tissues at the 1-month time point, and 
kidney tissue at the 2-month time point in WT diabetics compared to WT controls. Loss 
of MALAT1 prevented diabetes induced increase of inflammatory transcripts in both 
heart and kidneys after both one and two months of diabetes.  
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Real time RT-PCR analysis of TNFα, IL-6, and IL-1β in wild type (WT) control, WT 
diabetic (Dia), MALAT1-/- (MALAT1 KO) control, and MALAT1-/- 1-month diabetic 
mouse cardiac tissues. All three transcripts were significantly increased in diabetic mouse 
heart tissue compared to the WT controls. Loss of MALAT1 RNA prevented such 
increases in the MALAT1 KO diabetic group. [*p<0.05 compared to WT control; 
#p<0.05 compared to WT Dia; n=8-13; data (as a ratio to β-actin) expressed as mean ± 
SEM, normalized to controls]. 
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Figure 3.10: Inflammatory transcript expression at 1-month diabetes in heart tissue 
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Real time RT-PCR analysis of TNFα, IL-6, and IL-1β in wild type (WT) control, WT 
diabetic (Dia), MALAT1-/- (MALAT1 KO) control, and MALAT1-/- 1-month diabetic 
mouse renal tissue. All three genes were significantly increased in diabetic mouse kidney 
tissue compared to the WT controls. Loss of MALAT1 lncRNA prevented such increases 
in the MALAT1 KO diabetic group. [*p<0.05 compared to WT control; #p<0.05 
compared to WT Dia; n=6-10; data (as a ratio to β-actin) expressed as mean ± SEM, 
normalized to controls]. 
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Figure 3.11: Inflammatory transcript expression at 1-month diabetes in kidney tissue 
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Real time RT-PCR analysis of TNFα, IL-6, and IL-1β in wild type (WT) control, WT 
diabetic (Dia), MALAT1-/- (MALAT1 KO) control, and MALAT1-/- 2-month diabetic 
mouse cardiac tissue. All three genes were significantly increased in diabetic mouse heart 
tissue compared to the WT controls. Loss of  MALAT1 lncRNA prevented such 
increases in the MALAT1 KO diabetic group for both IL-1β and TNFα but not for IL-6. . 
[*p<0.05 compared to WT control; #p<0.05 compared to WT Dia; n=8-13; data (as a 
ratio to β-actin) expressed as mean ± SEM, normalized to controls]. 
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Figure 3.12: Inflammatory transcript expression at 2-month diabetes in heart tissue 
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Real time RT-PCR analysis of TNFα, IL-6, and IL-1β in wild type (WT) control, WT 
diabetic (Dia), MALAT1-/- (MALAT1 KO) control, and MALAT1-/- 2-month diabetic 
mouse renal tissue. All three transcripts were significantly increased in diabetic mouse 
kidney tissue compared to the WT controls. Loss of MALAT1 lncRNA prevented such 
increases in the MALAT1 KO diabetic group. MAlAT1 KO control mice had 
significantly less expression of all three genes than the WT control mice. [*p<0.05 
compared to WT control; #p<0.05 compared to WT Dia; n=4-9; data (as a ratio to β-
actin) expressed as mean ± SEM, normalized to controls]. 
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Figure 3.13: Inflammatory transcript expression at 2-month diabetes in kidney tissue 
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3.3.4 Protein expression 
This finding was then further confirmed using protein extract from kidney and heart. We 
used ELISAs to test for levels of the pro-inflammatory cytokines IL-6 and INFγ in tissue 
lysates from both heart and kidney and IL-1β in kidney. Our findings corroborated those 
of our transcript analyses and showed significant elevation in inflammatory cytokine 
production in WT diabetic animals, and protection from this increase in the MALAT1 
knockout diabetic animals for each of the cytokines tested in both tissues [Figures 3.14 
and 3.15].  
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ELISA for mouse IL-6 and INFγ in wild type (WT) control, WT diabetic (Dia), 
MALAT1-/- (MALAT1 KO) control, and MALAT1-/-diabetic 2-month cardiac tissue. 
Both cytokines were significantly increased in diabetic mouse heart tissue compared to 
the WT controls. Loss of MALAT1 lncRNA prevented such increases in the MALAT1 
KO diabetic group. MALAT1 KO control mice had comparable expression to WT 
control mice. [*p<0.05 compared to WT control; #p<0.05 compared to WT Dia; n=5-9; 
data expressed as mean ± SEM]. 
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Figure 3.14: Inflammatory cytokine expression in 2-month heart tissue 
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ELISAs for mouse IL-6, IL-1β, and INFγ in wild type (WT) control, WT diabetic (Dia), 
MALAT1-/- (MALAT1 KO) control, and MALAT1-/- diabetic 2-month renal tissue. All 
three cytokines were significantly increased in diabetic mouse kidney tissue compared to 
the WT controls. Loss of MALAT1 lncRNA prevented such increases in the MALAT1 
KO diabetic group. MALAT1 KO control mice had comparable expression to WT 
control mice. [*p<0.05 compared to WT control; #p<0.05 compared to WT Dia; n=5-9; 
data expressed as mean ± SEM]. 
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Figure 3.15: Inflammatory cytokine expression in 2-month kidney tissue  
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3.3.5 Potential interactions of MALAT1 
We looked at multiple genes of interest that may be involved in MALAT1 regulation or 
downstream of MALAT1. Three candidate genes were SAA3, NEAT1, and p53. SAA3, a 
regulator of inflammation, has previously been shown to be diminished in MALAT1 KO 
mice [66]. Our study supports this finding, as well as provides new evidence for 
MALAT1’s regulation of SAA3 using diabetic animals. SAA3 was found to be 
significantly elevated in the WT diabetic animals, but loss of MALAT1 lncRNA 
prevented this increase in both heart and kidney [Figures 3.16, 3.17]. We further 
examined two other potential molecules regulated by MALAT1 as proposed by literature, 
these being NEAT1 and p53. NEAT1 is the neighboring gene of MALAT1 and is also an 
evolutionary conserved lncRNA [83]. Neat1 was also shown to be elevated in the liver 
and brain cortex of MALAT1 knockout mice compared to WT animals in a previous 
study [66]. While diabetes had no significant effect on neat1, we confirmed that loss of 
MALAT1 led to significant increases in the transcript compared to WT animals in both 
the heart and kidney tissues [Figures 3.14, and 3.15]. P53 has been investigated as both 
an upstream as well as a downstream mediator of MALAT1 [89.92,93]. At 2-months post 
diabetes in the heart tissue, p53 transcript was significantly elevated compared to WT 
control animals, and this increase was attenuated in the MALAT1 KO diabetic animals 
[Figure 3.14]. However, in the kidney tissue, both MALAT1 KO groups and the diabetic 
WT animals had significantly elevated levels of p53, suggesting a tissue specific altered 
regulation [Figure 3.17].  
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Real time RT-PCR analysis of SAA3, p53, and neat1in wild type (WT) control, WT 
diabetic (Dia), MALAT1-/- (MALAT1 KO) control, and MALAT1-/- 2-month diabetic 
mouse cardiac tissues. SAA3 was not found to be significantly altered in diabetes. 
Relative abundance of p53 was significantly increased in the WT diabetic animals. Loss 
of MALAT1 lncRNA prevented such increases in the MALAT1 KO diabetic group. 
Neat1 transcript abundance was significantly increased in both MALAT1 KO groups. 
[*p<0.05 compared to WT control; #p<0.05 compared to WT Dia; n=6-10; data 
expressed (as a ratio to β-actin)  as mean ± SEM, normalized to controls]. 
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Figure 3.16: Molecular alterations downstream to malat1 knockout in 2-month heart tissue 
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Real time RT-PCR analysis of SAA3, p53 and Neat1 in wild type (WT) control, WT 
diabetic (Dia), MALAT1-/- (MALAT1 KO) control, and Malat1-/- diabetic 2-month 
diabetic mouse renal tissue. SAA3 was significantly increased in diabetic mouse kidney 
tissue compared to the WT controls. Loss of malat1 prevented such increases in the 
MALAT1 KO diabetic group. P53 was significantly increased in the WT diabetic mice as 
well as both MALAT1 KO groups compared to the WT controls. Transcript abundance of 
neat1 was significantly increased in both the MALAT1 KO groups compared to the WT 
control mice. [*p<0.05 compared to WT control; #p<0.05 compared to WT Dia; n=4-9; 
data (as a ratio to β-actin) expressed as mean ± SEM, normalized to controls]. 
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Figure 3.17: Molecular alterations downstream to MALAT1 lncRNA knockout in 2-month kidney tissue 
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3.4 Functional Analyses 
Renal and cardiac functional analyses were performed for both the kidneys and the heart 
to assess the effect of diabetes on target organ damage and whether such changes are 
specifically mediated through MALAT1 and other biochemical alterations.  
 
3.4.1 Albumin Creatinine Ratio (ACr ratio) 
ACr ratio was used to assess kidney function over the course of one day. This is a 
standard test for assessing kidney function [106,107]. Albumin is a large protein that is 
normally only present in the urine in very small quantities due to its large size being 
unable to pass through the glomeruli. In diabetes however, damage to the kidney by 
glucose-induced alterations leads to widening in pore sizes, which allows larger proteins 
to pass through and further damage the kidney. As such, albuminuria is one of the earliest 
and most characteristic functional changes in diabetic nephropathy [108]. Creatinine on 
the other hand is a protein compound that is released regularly over the course of a day as 
a by-product of normal muscle breakdown [109]. Lower as well as higher than normal 
creatinine levels have both been associated with diabetes; however, in most cases the 
levels do not appear to be altered in diabetes due to similar skeletal muscle abundances in 
diabetic and non-diabetic animals [110,111]. Briefly, two days before sacrifice, urine was 
collected for 24 hours and the total volume was recorded. Urine samples were kept and 
frozen in -80 °C to be used in future analyses. ELISAs were used independently to 
measure the amount of albumin and creatinine in the urine samples, the ratios were 
obtained, and were normalized to 24 hr urine volume.  The WT diabetic as well as the 
MALAT1 KO diabetic animals showed significantly increased ACr ratio compared to the 
WT control animals [Figure 3.18]. Loss of MALAT1 lncRNA had no effect on the ACr 
ratio in MALAT1 KO control animals.  
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Figure 3.18: Mouse 24 hr albumin: creatinine ratio in 2-month diabetic mice  
Urinary albumin/creatinine ratio measured in in wild type (WT) control, WT diabetic 
(Dia), MALAT1-/- (MALAT1 KO) control, and MALAT1-/- diabetic mice following 2 
months of STZ-induced diabetes. Diabetic animals had significantly higher 
albumin/creatinine ratios compared to the control animals. MALAT1 had no significant 
effect in reducing the diabetes-associated increase. [*p<0.05 compared to WT control; 
n=8-10; data expressed as mean ± SEM]. 
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3.4.2 Doppler Echocardiography 
In the heart, echocardiography was used to look at and measure blood flow in the left 
ventricle, as well as heart wall thickness. We used the VEVO2100 ultrasound to carry out 
this procedure 5 days prior to sacrifice. In diabetes, the heart loses some of its 
contractility due to changes in the cardiomyocytes. This causes normal blood flow 
patterns to be altered which can be measured using pulsewave Doppler [112]. The E/A 
wave ratio is one metric used to look at the amount of blood that moves through the 
mitral valve during normal filling of the left ventricle. In normal hearts, the majority of 
the blood moves in to the ventricle during the E (early) wave and a smaller remaining 
amount is pushed into the heart by arterial contraction in the A (late) wave. However, in 
diabetes, only about half the blood moves into the heart in the diastolic filling or E wave, 
and much more blood has to be pushed through during the A wave leading to a lower E/A 
ratio. Both MALAT1 control and WT control animals showed normal E/A ratios [Figure 
3.19]. WT diabetic animals had significantly decreased E/A ratios, indicating some 
diastolic dysfunction. Loss of MALAT1 in diabetic animals had partial protective effect 
on diabetes induced dysfunction. Supplemental data can be found in Table 3.1.  
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Figure 3.19: Loss of MALAT1 prevents functional alterations in heart contractility in 
diabetes 
 
Using a Vevo2100 ultrasound we conducted echocardiographic examinations to assess 
functional changes in heart contractility of MALAT1-/- ( MALAT1 KO)control, WT 
diabetic (Dia) and MALAT1-/- diabetic mice compared to wild-type (WT) control mice. 
2-month WT diabetic mice showed reduced E/A ratio compared to WT control animals. 
Such changes were partially corrected in the MALAT1 knockout diabetic animals. 
MALAT1 knockout control animals showed no differences in E/A ratio compared to WT 
control animals.  [*p<0.05 compared to WT control; #p<0.05 compared to WT Dia; 
compared to WT control; n=8-12; data expressed as mean ± SEM]. 
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Table 3.1:Echocardiographic data 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: WT-Co, wild type control; WT-Dia, wild type diabetes; MALAT1-Co; MALAT1 
knockout control, MALAT1-Dia; MALAT1 knockout with diabetes.  
WT-Co 
(n=6) 
Variable  
MALAT1-Co 
(n=6) 
WT-Dia 
  (n=6) 
MALAT1-Dia 
  (n=6) 
Diastolic Function 
Heart rate                   401±16        391±35.57          430±40.40          410±31.12 
 (beats/min) 
Haemodynamics 
E’/A’  ratio    1.585±0.155        1.675±0.141        1.29±0.103        1.410±0.132 
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Chapter 4  
4 Discussion 
 
This study looked at the role of MALAT1 in producing inflammatory cytokines in 
chronic diabetic complications. Here we have examined a novel mechanism that takes 
place in diabetes to regulate the production of inflammatory cytokines using a long non-
coding RNA. Furthermore, this is the first study to look at MALAT1 in a chronic diabetic 
animal model. This study expands on the current knowledge of diabetic complications 
and immune transcript regulation in the nucleus, and provides novel insight and findings 
in the field of lncRNA.   
 Inflammation is a key process in the development of diabetic complications 
[13,14]. High glucose in the blood initially leads to the impairment of glycolytic 
metabolism and an increase in reactive oxygen species in the cells. Oxidative DNA can 
then act as a danger-associated signal which can be recognized by internal receptors 
which trigger the production of these inflammatory molecules [34,35]. Low-grade 
chronic inflammation is continuously present in sites that are affected by the disease. This 
leads to a pro-inflammatory environment and recruitment of larger than normal numbers 
of inflammatory cells which mediate many of the pathologies associated with diabetic 
complications [13,14]. These conditions lead to continual damage to the inflamed tissues 
due to the secreted molecules and actions taken by the immune cells. Inflammation is 
also a key process involved in cancer metastasis where levels of MALAT1 RNA are 
greatly elevated. MALAT1 was also previously shown to be involved in the regulation of 
inflammatory cytokines in other systems [66,95].    
 We identified MALAT1 as one of many lncRNAs that was upregulated in 
endothelial cells when exposed to high glucose using an array. Using a local alignment 
tool, probe sequences were compared across the human genome and one was identified as 
a complete 60-nucleotide match identical to human MALAT1. In this case, MALAT1 
lncRNA was downregulated almost 3-fold in the human retinal endothelial cells 
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compared to the control treated cells.        
     
However, when we examined cells using RT-PCR to validate the array findings 
we were surprised to see a duration dependent alteration of glucose induced MALAT1 
expression. Although in keeping with array study, it was downregulated after 24hrs, 
following 48hrs of high glucose, it was increased. We confirmed these findings in two 
endothelial cells and then explored further effects of such upregulation. The exact reason 
for such variability is not clear. Several explanations may be put forward. The sensitivity 
of the assay (array vs. RT-PCR), and RNA degradation may both be in part responsible. 
In addition, other factors induced secondary to oxidative stress may also be responsible. 
Nevertheless, the biological significance of such alterations were demonstrated following 
siRNA mediated silencing [95].    
MALAT1 is one of the more characterized lncRNAs although it still remains 
largely unstudied due to its relatively recent discovery in 2003 [75]. Several papers have 
proposed functions or mechanisms for the molecule, but there is little consensus and 
novel findings continue to be reported. A likely reason for this may be due to tissue 
specific or cell-specific functions. MALAT1is expressed at high levels in nearly all cell 
types but it is quite possible that it does not exert the exact same function in each cell 
[89]. MALAT1 lncRNA is an extremely large molecule at 8.7 kb in humans, so it is even 
more likely that the molecule has multiple functions in a given cells rather than just one. 
MALAT1 is highly conserved evolutionarily [92], so it is possible that MALAT1 may 
have evolved to have a specific function that only presents itself under a particular stress. 
MALAT1 has been shown to be a true lncRNA [84]. It was shown recently that 
about five percent of proposed lncRNAs actually coded for small peptide sequences 
[103]. Several others are still debated due to their homology to protein coding transcripts 
or strong association with ribosomes. MALAT1 has been shown to be a long noncoding 
RNA through multiple means including bioinformatics analyses, localization, ribosomal 
affinity, and in vitro transcription-translation assays [78, 66]. Such assays use both 
biotechnological and quantitative experiments to look at the affinity of the transcript for 
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ribosomes, and the presence of specifically sized bands matching open reading frame 
(ORF) sizes in Western blots. We have also confirmed this ourselves using the 
bioinformatics software PhyloCSF which found MALAT1 RNA to be 1011 times to be 
better explained by a non-coding transcript model than a coding model. This software is 
also highly used and recognized due to its coding which allows it to not only consider 
known protein sequences but account for the possibility of uncharacterized or unknown 
sequence arrangements [101,102].    
Here we further show MALAT1 lncRNA is an exclusively nuclear lncRNA which 
again supports its classification as a lncRNA. This finding has been shown by other labs 
previously [66,86]. We do, however show that MALAT1 lncRNA localization in the 
nucleus does not appear to change under high glucose treatment. Using florescent probes 
specific to MALAT1 RNA we were able to show that (lncRNA) MALAT1 retains its 
focal expression pattern under both high and low glucose treatments in endothelial cells. 
No visual differences could be seen between HG and NG using this method, which is 
why RT-PCR analysis was conducted to show changes in MALAT1 expression more 
sensitively.  
We looked at MALAT1 expression levels and we compared levels of transcripts 
of interest using qRT-PCR in the high and low glucose treated cells. We first found that 
at 48-hours, MALAT1 was upregulated more than two fold in the high glucose treated 
cells compared to normal glucose treated cells. However, MALAT1 expression was not 
significantly different between the treated cells and controls at 6, 12, or 24 hours. This 
same pattern was identified in both HREC and HUVEC cells.  
Many transcripts have altered expression under high glucose treatment in 
endothelial cells and this is well documented [11,25]. Many genes involved in 
angiogenesis, the extra cellular matrix, repair and death pathways are elevated. Of 
particular interest to us though were the pro-inflammatory transcripts. These molecules 
such as IL-6, TNFα, IL-1β, and INFγ are involved in the initiation as well as sustaining 
an inflammatory response [13,14]. We found that the expression of these transcripts 
under high glucose closely matched the expression of MALAT1 in endothelial cells. Our 
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lab has shown previously that siRNA mediated silencing of MALAT1 prevented such 
upregulation of inflammatory molecules [95]. We then decided to look at MALAT1 
using an animal model of diabetes to better understand its role in vivo. We also focused 
on the key process of inflammation.         
    
To accomplish this, we obtained a MALAT1 deficient model through a 
collaboration with Dr. Spector [66]. This model and its development have been described 
previously, but briefly, it is a phenotypically normal mouse on a C57/BL6 background 
and is completely devoid of (lncRNA) MALAT1 in all tissues. There are no defects in 
breeding and the animals live past 2 years of age without intervention. The knockout was 
achieved with the excision of a roughly 3-kb segment that includes the MALAT1 5’ 
promoter. Two genes which were reported to be abnormally expressed at the transcript 
level in both the brain cortex and liver of the animals were SAA3 and NEAT1 [66]. 
NEAT1 is the neighboring gene of MALAT1 and is also a lncRNA. These two molecules 
are both highly conserved and nearly always located side by side, despite being on 
different chromosomes in different species including in mouse and rat. NEAT1was found 
to have increased expression in the analyzed tissues in the MALAT1 knockout mouse 
[77]. SAA3 is a gene involved in the regulation of inflammatory molecules. It is normally 
expressed at high levels in the liver but in the MALAT1 knockout model, its expression 
was significantly decreased. This finding combined with our finding of a decreased 
inflammatory marker in MALAT1 KO mice, combined with our increased inflammatory 
markers in HG treated cells which also had increased expression of MALAT1 led us to 
focus on a role for the MALAT1 lncRNA in the regulation of inflammatory molecules. 
  
We only used male mice in this study as we were not looking for gender specific 
differences at this time and did not want to include additional variables to the study. 
Diabetes was induced in animals at 10 weeks of age using STZ. We used four different 
time points in this study of 1, 2, 4, and 8 weeks of diabetes. Loss of MALAT1 had no 
effect on blood glucose levels and all groups of diabetic animals had nearly identical 
blood glucose levels both before and after STZ induced diabetes. Additionally, loss of 
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MALAT1 had no effect on polyuria or glucosuria in the diabetic animals. While diabetic, 
MALAT1 knockout animals did not lose the same amount of body weight as their age- 
sex- matched controls. We focused on the heart and kidney due to their abundant tissue 
supply and importance in two major diabetic complications.    
MALAT1 expression in the heart and kidney tissues of WT diabetic mice was 
initially increased but then significantly decreased at 2, 4 and 8 weeks of diabetes. This 
finding was somewhat confusing. In the cell culture system, we found that high glucose 
caused increased MALAT1 expression in endothelial cells 48 hours after incubation with 
high glucose. Several possible explanations may be put forward. Tissues contain multiple 
cell types which interact with each other. Our initial cell culture studies were performed 
in HUVECS and HRECS where we showed glucose-induced MALAT1 upregulation. 
However, previous studies on other molecules have reported cell specific variations under 
the same conditions. Despite endothelial cells being the principal cell influenced by 
hyperglycemia, other cell types make up a larger portion of the tissues and could 
influence MALAT1 lncRNA levels.  Moreover, direct extrapolation from cell culture in 
to tissue may not always be feasible. The data however, are in keeping with our array 
data, which showed downregulation of MALAT1 after 24 hours. Nevertheless, such an 
increase in MALAT1 expression in diabetes was sufficient to trigger inflammatory 
cytokine expression as evidenced by the inhibition of such changes in the knockout mice. 
It is of interest to note that in the WT diabetic mice, this initial upregulation of MALAT1 
was capable of a sustained effect. The changes in MALAT1 expression from 2 to 8 weeks 
may indicate the possibility of a compensatory mechanism, whereby the system attempts 
to decrease MALAT1 expression to reduce the presence of inflammatory cytokines. An 
alternative possibility would be MALAT1 induction of an epigenetic regulatory change. 
Such a change would be inducible by the increase in MALAT1 transcript and then 
sustained even if MALAT1 RNA levels dropped off later [EPI]. The exact mechanism of 
MALAT1’s regulation and action in the nucleus in producing such changes remains to be 
explained.  
At both 1 and 2-months, inflammatory transcript levels were increased in the WT 
diabetic animals as was expected and has been previously reported. However, an exciting 
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finding was that in both heart and kidney tissues at both 1 and 2-months of diabetes, 
inflammatory transcript levels were not elevated at all and were maintained at WT 
control or even under WT control animal levels in the MALAT1 KO mice. This 
suggested that loss of MALAT1 had a protective effect, which inhibited the increased 
normally seen in diabetes.   
This finding was then further supported by the examination of protein levels from 
2-month animal tissues. These findings closely matched those of our transcripts where 
the significant increases in pro-inflammatory molecules associated with diabetes were 
prevented in the diabetic MALAT1 knockout animals. We further went on to look at 
functional differences and consequences this change in inflammatory status might have 
using the albumin: creatinine ratio from urine taken from the animals, and using 
echocardiography data that had been collected prior to sacrifice.   
E/A ratio which is a measurement of left ventricular diastolic function was 
significantly decreased in WT diabetic animals indicating some dysfunction; however, 
this decrease was attenuated in the MALAT1 knockout diabetic animals again supporting 
our findings that the loss of MALAT1 has a protective effect. Despite this, we determined 
using the previously collected urine that the ACr was not significantly different between 
the WT and knockout diabetic animal groups. All values for albumin concentration, 
creatinine concentration, and 24-hour urine output were similar for the two groups 
leading to no significant differences between them. This suggests that the damage to the 
glomeruli in filtration due to diabetes may be more detrimental to the kidneys than the 
loss of MALAT1 can compensate for.  Alternatively, MALAT1 activity may not 
contribute as significantly to kidney dysfunction as heart dysfunction. The differential 
effect of MALAT1 inhibition on renal and cardiac function may also suggest possible 
tissue specific pathogenetic roles of this molecule.  
We also examined a few different mechanisms and interactions MALAT1 may 
have with other molecules. Three of these molecules were neat1, SAA3, and p53. 
NEAT1 is the neighboring gene of MALAT1 and changes in its expression may reflect 
limitations and compensations in our animal model that we need to address. In a previous 
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study, NEAT1 has also been shown to have a regulatory role in diabetic retinopathy [76]. 
As in the case of Zhang et al., we found NEAT1 levels to be significantly elevated in our 
two knockout MALAT1 mouse groups, suggesting that the molecules might regulate in –
cis [66]. Neat1 expression did not however appear to change in diabetes. Neat1 has been 
looked at recently as a potential regulator of inflammatory molecules in cells so it is 
possible that MALAT1 exerts a regulatory role on NEAT1 or visa-versa. The molecules 
may also compensate to some degree as their functions remain largely unknown. Dual 
knockout MALAT1 and NEAT1 mice have not yet been attempted and may provide a 
phenotype which the two individual knockouts on their own seemingly lack.   
MALAT1 has previously been shown to regulate SAA3 in mice, as well as 
inflammatory cytokines in cells induced with hyperglycemia [66,95]. Here we validate 
those findings but use a diabetic animal model to show that this mechanism involving 
MALAT1 holds true in vivo and in multiple complex organs. As with the other 
inflammatory molecules, SAA3 transcript expression was increased in the WT diabetic 
animals, and this increased expression was eliminated in both the heart and kidney tissues 
at both the 1 and 2-month time points.  
Unlike in cancer where MALAT1 lncRNA levels are found to be at extremely 
high levels [76,82,87], here we have found an initial surge of MALAT1 RNA, followed 
by decreased expression. One reason we speculate this might be due to a compensatory 
mechanism where the cells attempt to decrease the amount of inflammatory cytokines 
being produced by reducing expression of MALAT1. Another potential mechanism 
involves p53 feedback which is completely absent in cancer, but found at elevated levels 
in diabetes. In this system, p53 appeared to be a downstream target of MALAT1. These 
data are in keeping with past research by other investigators. A third reason could be due 
to functional redundancy with other RNA transcripts such as its neighboring gene 
NEAT1. While we did see a decrease in inflammatory cytokine expression, it is possible 
other effects of the loss of MALAT1 were compensated for by other molecules. Due to 
its size and high basal expression levels in most tissues , the potential number of 
interactions MALAT1 can have is quite substantial so uncovering more about the 
regulatory process is essential to understanding more about MALAT1’s mechanism. 
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MALAT1 could also have tissue dependent functions that carry, though here we are able 
to show consistent suppression of inflammatory molecules in tissues that have lost 
MALAT1 expression. 
 
4.1 Future Studies 
Here we have identified MALAT1 as an intermediary molecule in the 
transcriptional pathway involved in producing inflammatory cytokines in diabetic tissues. 
MALAT1 is already known to be important in other diseases and pathologies, but its 
mechanism is largely unknown. Despite this, MALAT1 is not essential for life or 
development in vivo and its lack of coding potential and strong conservation between 
species make it a good candidate for RNA based therapies.  
MALAT1 is still relatively unstudied at this point and there are many more follow-up 
studies need to uncover its function in diabetes, as well as in normal healthy tissues. 
In this study we have shown MALAT1 is initially upregulated and then downregulated in 
the type-1 STZ-induced diabetic mouse model, but taking this study in to a type 2 
diabetic model such as the db/db mouse, or other diabetic model would help validate our 
findings or even provide novel insights in MALAT1 function. Using a different animal 
model of diabetes might also allow us to uncover stronger associations between 
MALAT1 and its downstream targets. Additionally, looking at later time-points such as 4 
and 6 months after the onset of diabetes would potentially be able to show a stronger 
protective effect on reducing inflammatory cytokines and protecting cardiac function due 
to the gradual progression and worsening of complications in the WT-diabetic mouse.  
In this study we have focused on afflictions of the heart and kidney, but other tissues such 
as the retina and cerebral cortex might also provide novel insights in to the effects of 
MALAT1 in other tissues. We also noticed differences in the heart and kidney with 
respect to functional differences after the loss of MALAT1 in diabetes. Conducting cell 
specific studies for these tissues using podocytes or cardiomyocytes might help to 
understand these differences. 
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Whether MALAT1 lncRNA has the same effect in all tissues, or enters a tissue specific 
function remains unclear. Future work on the function of MALAT1 and its role in 
diseases like diabetes will improve our understanding of why this lncRNA has such high 
levels of expression and strong evolutionary conservation, potentially paving the way to 
new discoveries in the large family of lncRNA.   
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